658.7K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 90,601 | 358,636 (0%) | 0% | 0 | Common Stock | |
| Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 13,288 | 49,763 (0%) | 0% | 0 | Common Stock | |
| Phillip G. Febbo | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 24,160 | 106,700 (0%) | 0% | 0 | Common Stock | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 30,200 | 143,899 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 30,200 | 100,508 (0%) | 0% | 0 | Common Stock | |
| John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 06 Mar 2025 | 2,400 | 105,260 (0%) | 0% | 31.0 | 74,484 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 36,240 | 107,660 (0%) | 0% | 0 | Common Stock | |
| John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 31.96 per share. | 06 Mar 2025 | 5,011 | 100,249 (0%) | 0% | 32.0 | 160,146 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.37 per share. | 04 Mar 2025 | 1,094 | 268,035 (0%) | 0% | 34.4 | 37,599 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.82 per share. | 04 Mar 2025 | 28,189 | 292,543 (0%) | 0% | 32.8 | 925,248 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.91 per share. | 04 Mar 2025 | 23,414 | 269,129 (0%) | 0% | 33.9 | 794,009 | Common Stock |
| Phillip G. Febbo | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 33.95 per share. | 04 Mar 2025 | 3,570 | 82,540 (0%) | 0% | 34.0 | 121,205 | Common Stock |
| Phillip G. Febbo | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 04 Mar 2025 | 4,467 | 86,110 (0%) | 0% | 32.9 | 146,808 | Common Stock |
| Annie McGuire | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 33.69 per share. | 04 Mar 2025 | 1,142 | 70,308 (0%) | 0% | 33.7 | 38,476 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 02 Mar 2025 | 4,301 | 36,475 (0%) | 0% | 34.8 | 149,503 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 20,324 | 320,732 (0%) | 0% | 34.8 | 706,462 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 34,273 | 341,056 (0%) | 0% | 33.8 | 1,159,798 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 67,277 | 375,329 (0%) | 0% | 0 | Common Stock | |
| Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 6,754 | 90,577 (0%) | 0% | 34.8 | 234,769 | Common Stock |
| Phillip G. Febbo | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 30,589 | 113,003 (0%) | 0% | 0 | Common Stock | |
| Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 15,672 | 97,331 (0%) | 0% | 33.8 | 530,340 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 11,070 | 113,699 (0%) | 0% | 34.8 | 384,793 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 11,911 | 124,769 (0%) | 0% | 33.8 | 403,068 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 23,170 | 136,680 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 13,466 | 86,705 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 7,000 | 79,705 (0%) | 0% | 33.8 | 236,880 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 8,255 | 71,450 (0%) | 0% | 34.8 | 286,944 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 11,006 | 84,816 (0%) | 0% | 0 | Common Stock | |
| John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 33.84 per share. | 27 Feb 2025 | 5,746 | 79,070 (0%) | 0% | 33.8 | 194,445 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 7,650 | 71,420 (0%) | 0% | 34.8 | 265,914 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.85 per share. | 03 Feb 2025 | 527 | 113,510 (0%) | 0% | 43.9 | 23,109 | Common Stock |
| Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 Jan 2025 | 20,000 | 64,598 (0%) | 0% | 8.0 | 160,800 | Common Stock |
| Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.28 per share. | 02 Jan 2025 | 10,000 | 28,497 (0%) | 0% | 5.3 | 52,800 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 40.12 per share. | 02 Jan 2025 | 5,309 | 23,188 (0%) | 0% | 40.1 | 213,010 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 40.50 per share. | 02 Jan 2025 | 4,691 | 18,497 (0%) | 0% | 40.5 | 189,996 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.14 per share. | 13 Dec 2024 | 400 | 307,345 (0%) | 0% | 44.1 | 17,657 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.37 per share. | 13 Dec 2024 | 5,190 | 307,745 (0%) | 0% | 43.4 | 225,080 | Common Stock |
| Phillip G. Febbo | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 44.09 per share. | 04 Dec 2024 | 3,934 | 82,414 (0%) | 0% | 44.1 | 173,447 | Common Stock |
| Annie McGuire | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 44.02 per share. | 04 Dec 2024 | 18,699 | 72,869 (0%) | 0% | 44.0 | 823,179 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 5,748 | 312,935 (0%) | 0% | 44.1 | 253,602 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 1,087 | 41,226 (0%) | 0% | 44.1 | 47,958 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 43.36 per share. | 02 Dec 2024 | 956 | 40,270 (0%) | 0% | 43.4 | 41,452 | Common Stock |
| Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 6,738 | 86,348 (0%) | 0% | 44.1 | 297,281 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.23 per share. | 02 Dec 2024 | 7,000 | 114,037 (0%) | 0% | 43.2 | 302,622 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 3,464 | 121,037 (0%) | 0% | 44.1 | 152,832 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 1,918 | 91,568 (0%) | 0% | 44.1 | 84,622 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 43.25 per share. | 02 Dec 2024 | 1,050 | 73,810 (0%) | 0% | 43.2 | 45,408 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 1,314 | 74,860 (0%) | 0% | 44.1 | 57,974 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 42.89 per share. | 27 Nov 2024 | 5,032 | 42,313 (0%) | 0% | 42.9 | 215,834 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 36.77 per share. | 19 Nov 2024 | 1,600 | 31,628 (0%) | 0% | 36.8 | 58,826 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 38.76 per share. | 19 Nov 2024 | 10,125 | 18,497 (0%) | 0% | 38.8 | 392,405 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 37.77 per share. | 19 Nov 2024 | 3,006 | 28,622 (0%) | 0% | 37.8 | 113,538 | Common Stock |
| Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 15,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Robert S. Epstein | Director | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 12 Nov 2024 | 15,000 | 44,598 (0%) | 0% | 38.3 | 574,830 | Common Stock |
| Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 12 Nov 2024 | 15,000 | 59,598 (0%) | 0% | 8.0 | 120,600 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.34 per share. | 12 Nov 2024 | 15,275 | 124,501 (0%) | 0% | 38.3 | 585,663 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 35.23 per share. | 19 Sep 2024 | 5,173 | 0 (0%) | 0% | 35.2 | 182,263 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 29.78 per share. | 04 Sep 2024 | 5,479 | 76,174 (0%) | 0% | 29.8 | 163,159 | Common Stock |
| Brent Shafer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 16,507 | 16,507 (0%) | 0% | 0 | Common Stock | |
| Tom Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 16,507 | 16,507 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 5,748 | 318,683 (0%) | 0% | 31.5 | 181,349 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 1,087 | 47,345 (0%) | 0% | 31.6 | 34,295 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 3,464 | 139,776 (0%) | 0% | 31.5 | 109,289 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 1,920 | 93,486 (0%) | 0% | 31.6 | 60,576 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 1,315 | 81,653 (0%) | 0% | 31.5 | 41,488 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 12 Aug 2024 | 99 | 46,314 (0%) | 0% | 30.0 | 2,971 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 8,486 | 0 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 32.77 per share. | 12 Aug 2024 | 912 | 5,173 (0%) | 0% | 32.8 | 29,884 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 32.36 per share. | 12 Aug 2024 | 22,407 | 6,085 (0%) | 0% | 32.4 | 725,026 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 31.19 per share. | 12 Aug 2024 | 3,869 | 28,492 (0%) | 0% | 31.2 | 120,655 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 32.77 per share. | 12 Aug 2024 | 688 | 34,343 (0%) | 0% | 32.8 | 22,544 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 32.36 per share. | 12 Aug 2024 | 16,838 | 35,031 (0%) | 0% | 32.4 | 544,851 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 31.19 per share. | 12 Aug 2024 | 2,931 | 51,869 (0%) | 0% | 31.2 | 91,406 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.41 per share. | 12 Aug 2024 | 8,486 | 54,800 (0%) | 0% | 10.4 | 88,339 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 12 Aug 2024 | 101 | 32,361 (0%) | 0% | 30.0 | 3,031 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.41 per share. | 09 Aug 2024 | 300 | 47,445 (0%) | 0% | 10.4 | 3,123 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 300 | 8,486 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 09 Aug 2024 | 746 | 32,462 (0%) | 0% | 30.0 | 22,402 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 09 Aug 2024 | 1,032 | 46,413 (0%) | 0% | 30.0 | 30,990 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2024 | 1,214 | 8,786 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.32 per share. | 07 Aug 2024 | 5,108 | 45,180 (0%) | 0% | 30.3 | 154,883 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.41 per share. | 07 Aug 2024 | 1,214 | 50,288 (0%) | 0% | 10.4 | 12,638 | Common Stock |
| Jens Holstein | Director | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 07 Aug 2024 | 2,500 | 30,378 (0%) | 0% | 28 | 70,000 | Common Stock |
| Jens Holstein | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 07 Aug 2024 | 2,500 | 27,878 (0%) | 0% | 30 | 75,000 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.32 per share. | 07 Aug 2024 | 1,965 | 33,208 (0%) | 0% | 30.3 | 59,582 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.32 per share. | 07 Aug 2024 | 3,143 | 47,145 (0%) | 0% | 30.3 | 95,301 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Jul 2024 | 7,500 | 33,228 (0%) | 0% | 25 | 187,500 | Common Stock |
| Jens Holstein | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Jul 2024 | 2,500 | 32,878 (0%) | 0% | 25 | 62,500 | Common Stock |
| Jens Holstein | Director | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 16 Jul 2024 | 2,500 | 35,378 (0%) | 0% | 24 | 60,000 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Jul 2024 | 1,277 | 82,968 (0%) | 0% | 25 | 31,925 | Common Stock |
| Evan Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 49,074 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 40,728 (0%) | 0% | 0 | Common Stock | |
| Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 44,598 (0%) | 0% | 0 | Common Stock | |
| Jens Holstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 37,878 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 34,578 (0%) | 0% | 0 | Common Stock | |
| Eliav Barr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 41,868 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 20.59 per share. | 11 Jun 2024 | 3,870 | 29,255 (0%) | 0% | 20.6 | 79,683 | Common Stock |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 20.32 per share. | 10 Jun 2024 | 3,870 | 23,105 (0%) | 0% | 20.3 | 78,634 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 2,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 20.97 per share. | 07 Jun 2024 | 2,500 | 33,125 (0%) | 0% | 21.0 | 52,425 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.41 per share. | 07 Jun 2024 | 2,500 | 35,625 (0%) | 0% | 10.4 | 26,025 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 5,746 | 323,994 (0%) | 0% | 20.8 | 119,230 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 1,087 | 47,971 (0%) | 0% | 20.7 | 22,555 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 3,462 | 143,240 (0%) | 0% | 20.8 | 71,837 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 1,919 | 95,406 (0%) | 0% | 20.7 | 39,819 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 1,314 | 84,245 (0%) | 0% | 20.8 | 27,266 | Common Stock |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 28 May 2024 | 1,539 | 26,975 (0%) | 0% | 21 | 32,319 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 21.65 per share. | 01 Apr 2024 | 10,000 | 33,125 (0%) | 0% | 21.7 | 216,528 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 01 Apr 2024 | 10,000 | 43,125 (0%) | 0% | 13.2 | 131,900 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.10 per share. | 15 Mar 2024 | 5,971 | 329,740 (0%) | 0% | 21.1 | 125,988 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,780 | 335,711 (0%) | 0% | 0 | Common Stock | |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.10 per share. | 15 Mar 2024 | 2,189 | 146,702 (0%) | 0% | 21.1 | 46,188 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 4,318 | 148,891 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 114,724 | 323,931 (0%) | 0% | 0 | Common Stock | |
| Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 23,942 | 49,058 (0%) | 0% | 0 | Common Stock | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 59,856 | 144,573 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 49,880 | 97,325 (0%) | 0% | 0 | Common Stock | |
| John Leite | Chief Commercial Officer-CLIA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 49,880 | 85,559 (0%) | 0% | 0 | Common Stock | |
| Phillip G. Febbo | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 39,904 | 93,086 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 13,286 | 209,207 (0%) | 0% | 24 | 318,864 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 2,337 | 25,116 (0%) | 0% | 24 | 56,088 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 6,112 | 84,717 (0%) | 0% | 24 | 146,688 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 4,347 | 47,445 (0%) | 0% | 24 | 104,328 | Common Stock |
| John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 3,008 | 35,679 (0%) | 0% | 24 | 72,192 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 24.36 per share. | 01 Mar 2024 | 10,000 | 37,601 (0%) | 0% | 24.4 | 243,599 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.19 per share. | 01 Mar 2024 | 10,000 | 47,601 (0%) | 0% | 13.2 | 131,900 | Common Stock |
| Leite John | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 556 | 38,687 (0%) | 0% | 26.5 | 14,756 | Common Stock |
| Wygant Jonathan | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 507 | 27,020 (0%) | 0% | 26.5 | 13,456 | Common Stock |
| A. Stapley Marc | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 3,203 | 221,882 (0%) | 0% | 26.5 | 85,008 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 1,800 | 90,829 (0%) | 0% | 26.5 | 47,772 | Common Stock |
| McGuire Annie | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 803 | 51,792 (0%) | 0% | 26.5 | 21,312 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.14 per share. | 19 Jul 2023 | 838 | 37,601 (0%) | 0% | 30.1 | 25,257 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.17 per share. | 19 Jul 2023 | 3,090 | 35,173 (0%) | 0% | 30.2 | 93,232 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.07 per share. | 17 Jul 2023 | 19,095 | 40,763 (0%) | 0% | 30.1 | 574,106 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.19 per share. | 17 Jul 2023 | 7,441 | 38,263 (0%) | 0% | 30.2 | 224,616 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.16 per share. | 17 Jul 2023 | 2,324 | 38,439 (0%) | 0% | 30.2 | 70,090 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.07 per share. | 17 Jul 2023 | 23,949 | 45,704 (0%) | 0% | 30.1 | 720,106 | Common Stock |
| John L. Bishop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.37 per share. | 17 Jul 2023 | 10,000 | 43,125 (0%) | 0% | 6.4 | 63,700 | Common Stock |
| John L. Bishop | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 17 Jul 2023 | 10,000 | 33,125 (0%) | 0% | 30.0 | 300,002 | Common Stock |
| John L. Bishop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.37 per share. | 17 Jul 2023 | 10,000 | 43,125 (0%) | 0% | 6.4 | 63,700 | Common Stock |
| John L. Bishop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 10,000 | 15,000 | - | - | Stock Option (right to buy) | |
| John L. Bishop | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 10,000 | 25,000 | - | - | Stock Option (right to buy) | |
| John L. Bishop | Director | Sale of securities on an exchange or to another person at price $ 30.50 per share. | 17 Jul 2023 | 10,000 | 33,125 (0%) | 0% | 30.5 | 305,000 | Common Stock |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 16 Jun 2023 | 100 | 28,514 (0%) | 0% | 27.1 | 2,709 | Common Stock |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 26.42 per share. | 16 Jun 2023 | 5,793 | 28,614 (0%) | 0% | 26.4 | 153,077 | Common Stock |
| Evan Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 59,858 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 33,125 (0%) | 0% | 0 | Common Stock | |
| John L. Bishop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 33,125 (0%) | 0% | 0 | Common Stock | |
| Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 33,125 (0%) | 0% | 0 | Common Stock | |
| Jens Holstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 26,405 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 34,407 (0%) | 0% | 0 | Common Stock | |
| Eliav Barr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 30,395 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 3,203 | 227,696 (0%) | 0% | 26.7 | 85,584 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 260 | 28,354 (0%) | 0% | 26.7 | 6,947 | Common Stock |
| Bonnie H. Anderson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 1,304 | 41,377 (0%) | 0% | 26.7 | 34,843 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 1,183 | 95,754 (0%) | 0% | 26.7 | 31,610 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 494 | 54,324 (0%) | 0% | 26.7 | 13,200 | Common Stock |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 25.91 per share. | 30 May 2023 | 1,539 | 24,733 (0%) | 0% | 25.9 | 39,875 | Common Stock |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 34,000 | 34,117 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 14 Apr 2023 | 34,000 | 76,681 (0%) | 0% | 5.6 | 190,740 | Common Stock |
| Bonnie H. Anderson | Director | Sale of securities on an exchange or to another person at price $ 22.04 per share. | 14 Apr 2023 | 34,000 | 42,681 (0%) | 0% | 22.0 | 749,357 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 18,750 | 0 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.12 per share. | 16 Mar 2023 | 18,750 | 42,201 (0%) | 0% | 12.1 | 227,250 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 22.78 per share. | 16 Mar 2023 | 18,750 | 23,451 (0%) | 0% | 22.8 | 427,044 | Common Stock |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 34,000 | 68,117 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director | Sale of securities on an exchange or to another person at price $ 22.76 per share. | 15 Mar 2023 | 34,000 | 53,967 (0%) | 0% | 22.8 | 773,888 | Common Stock |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 15 Mar 2023 | 34,000 | 87,967 (0%) | 0% | 5.6 | 190,740 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 78,044 | 230,899 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 128,869 | 128,869 | - | - | Stock Option (right to buy) | |
| Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 8,868 | 28,614 (0%) | 0% | 0 | Common Stock | |
| Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,213 | 14,213 | - | - | Stock Option (right to buy) | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 26,014 | 96,937 (0%) | 0% | 0 | Common Stock | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 42,956 | 42,956 | - | - | Stock Option (right to buy) | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,413 | 54,818 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 38,660 | 38,660 | - | - | Stock Option (right to buy) | |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 6,029 | 152,855 (0%) | 0% | 24.1 | 145,299 | Common Stock |
| Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 1,224 | 19,746 (0%) | 0% | 24.1 | 29,498 | Common Stock |
| Bonnie H. Anderson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 8,994 | 53,967 (0%) | 0% | 24.1 | 216,755 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 2,726 | 70,923 (0%) | 0% | 24.1 | 65,697 | Common Stock |
| Annie McGuire | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 2,152 | 31,405 (0%) | 0% | 24.1 | 51,863 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 28 Feb 2023 | 10,000 | 23,451 (0%) | 0% | 25.0 | 250,001 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 10,000 | 18,750 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.12 per share. | 28 Feb 2023 | 10,000 | 33,451 (0%) | 0% | 12.1 | 121,200 | Common Stock |
| Bonnie H. Anderson | Director | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 17 Jan 2023 | 29,506 | 67,455 (0%) | 0% | 26.3 | 776,111 | Common Stock |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 34,000 | 102,117 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director | Sale of securities on an exchange or to another person at price $ 26.64 per share. | 17 Jan 2023 | 4,494 | 62,961 (0%) | 0% | 26.6 | 119,726 | Common Stock |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 17 Jan 2023 | 34,000 | 96,961 (0%) | 0% | 5.6 | 190,740 | Common Stock |
| Bonnie H. Anderson | Director | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 11 Jan 2023 | 63,247 | 62,961 (0%) | 0% | 25.1 | 1,589,195 | Common Stock |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2023 | 63,247 | 26,753 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.34 per share. | 11 Jan 2023 | 63,247 | 126,208 (0%) | 0% | 14.3 | 906,962 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 31.65 per share. | 13 Dec 2022 | 300 | 50,784 (0%) | 0% | 31.6 | 9,494 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.51 per share. | 13 Dec 2022 | 1,367 | 51,084 (0%) | 0% | 30.5 | 41,703 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 27.03 per share. | 06 Dec 2022 | 1,023 | 65,970 (0%) | 0% | 27.0 | 27,652 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 1,012 | 158,299 (0%) | 0% | 29.1 | 29,490 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 2,042 | 62,961 (0%) | 0% | 29.1 | 59,504 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 1,008 | 66,993 (0%) | 0% | 29.1 | 29,373 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 735 | 72,998 (0%) | 0% | 29.1 | 21,418 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 01 Dec 2022 | 30,000 | 145,003 (0%) | 0% | 5.6 | 168,300 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 30,000 | 136,117 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 50,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 28.60 per share. | 01 Dec 2022 | 45,460 | 65,003 (0%) | 0% | 28.6 | 1,300,301 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 27.81 per share. | 01 Dec 2022 | 34,540 | 110,463 (0%) | 0% | 27.8 | 960,447 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.34 per share. | 01 Dec 2022 | 50,000 | 115,003 (0%) | 0% | 14.3 | 717,000 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 30.21 per share. | 11 Nov 2022 | 5,900 | 52,551 (0%) | 0% | 30.2 | 178,255 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 31.02 per share. | 11 Nov 2022 | 100 | 52,451 (0%) | 0% | 31.0 | 3,102 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 11 Nov 2022 | 2 | 68,003 (0%) | 0% | 14.5 | 29 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2022 | 2 | 0 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 29.50 per share. | 11 Nov 2022 | 2 | 68,001 (0%) | 0% | 29.5 | 59 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2022 | 1,023 | 68,001 (0%) | 0% | 25 | 25,575 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 13 Oct 2022 | 1,844 | 66,847 (0%) | 0% | 8.9 | 16,338 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 9,244 | 300,756 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,844 | 0 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 13 Oct 2022 | 9,244 | 76,091 (0%) | 0% | 9.0 | 83,658 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 1,012 | 159,311 (0%) | 0% | 19.2 | 19,410 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 2,042 | 65,003 (0%) | 0% | 19.2 | 39,166 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 1,008 | 69,024 (0%) | 0% | 19.2 | 19,333 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 3,023 | 73,733 (0%) | 0% | 19.2 | 57,981 | Common Stock |
| Eliav Barr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 20,721 | 20,721 (0%) | 0% | 0 | Common Stock | |
| Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 14,598 | 14,598 | - | - | Stock Option (right to buy) | |
| Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 8,561 | 20,561 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 27.24 per share. | 05 Aug 2022 | 39,231 | 118,195 (0%) | 0% | 27.2 | 1,068,578 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 27.82 per share. | 05 Aug 2022 | 5,769 | 112,426 (0%) | 0% | 27.8 | 160,497 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 27.71 per share. | 05 Aug 2022 | 76,917 | 157,426 (0%) | 0% | 27.7 | 2,131,370 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 1 | 0 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 10,702 | 71,055 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.50 per share. | 05 Aug 2022 | 2 | 71,057 (0%) | 0% | 10.5 | 21 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.50 per share. | 05 Aug 2022 | 2 | 71,059 (0%) | 0% | 6.5 | 13 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 05 Aug 2022 | 1 | 71,060 (0%) | 0% | 5 | 5 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 26.54 per share. | 05 Aug 2022 | 1,028 | 70,032 (0%) | 0% | 26.5 | 27,283 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 18,248 | 18,248 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 2 | 0 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 2 | 0 | - | - | Stock Option (right to buy) | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 21,404 | 76,756 (0%) | 0% | 0 | Common Stock | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 36,496 | 36,496 | - | - | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 10,702 | 33,557 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 18,248 | 18,248 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 58,451 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 23,451 (0%) | 0% | 0 | Common Stock | |
| John L. Bishop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 23,451 (0%) | 0% | 0 | Common Stock | |
| Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 23,451 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 26,272 (0%) | 0% | 0 | Common Stock | |
| Jens Holstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 14,731 | 16,731 (0%) | 0% | 0 | Common Stock | |
| Jens Holstein | Director | Sale of securities on an exchange or to another person at price $ 16.27 per share. | 14 Jun 2022 | 8,720 | 2,000 (0%) | 0% | 16.3 | 141,846 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.33 per share. | 10 Jun 2022 | 60,000 | 159,761 (0%) | 0% | 16.3 | 980,094 | Common Stock |
| Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 18.50 per share. | 08 Jun 2022 | 15,000 | 8,720 (0%) | 0% | 18.5 | 277,502 | Common Stock |
| Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 08 Jun 2022 | 15,000 | 23,720 (0%) | 0% | 7.4 | 110,850 | Common Stock |
| Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 02 Jun 2022 | 4,047 | 99,761 (0%) | 0% | 18.2 | 73,777 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 02 Jun 2022 | 2,042 | 67,045 (0%) | 0% | 18.2 | 37,226 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 02 Jun 2022 | 1,008 | 60,353 (0%) | 0% | 18.2 | 18,376 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.47 per share. | 01 May 2022 | 736 | 85,952 (0%) | 0% | 20.5 | 15,066 | Common Stock |
| Nova Susan Tina | President, CLIA U.S. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 56,546 | 76,988 (0%) | 0% | 0 | Common Stock | |
| Nova Susan Tina | President, CLIA U.S. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 103,043 | 103,043 | - | - | Stock Option (right to buy) | |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 56,537 | 103,808 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 103,026 | 103,026 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 32,195 | 32,195 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 17,667 | 86,688 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 42,412 | 79,987 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 77,287 | 77,287 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 4,407 | 0 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 25.70 per share. | 03 Mar 2022 | 5,844 | 61,461 (0%) | 0% | 25.7 | 150,189 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 26.49 per share. | 03 Mar 2022 | 100 | 61,361 (0%) | 0% | 26.5 | 2,649 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 24.91 per share. | 03 Mar 2022 | 17,089 | 67,305 (0%) | 0% | 24.9 | 425,697 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 03 Mar 2022 | 4,407 | 84,394 (0%) | 0% | 6.0 | 26,354 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 37,773 | 37,773 | - | - | Stock Option (right to buy) | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 20,728 | 54,728 (0%) | 0% | 0 | Common Stock | |
| Nova Susan Tina | President, CLIA U.S. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.84 per share. | 02 Mar 2022 | 10,695 | 20,442 (0%) | 0% | 27.8 | 297,749 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.84 per share. | 02 Mar 2022 | 4,521 | 69,021 (0%) | 0% | 27.8 | 125,865 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.84 per share. | 02 Mar 2022 | 10,337 | 37,575 (0%) | 0% | 27.8 | 287,782 | Common Stock |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 22,855 | 22,855 (0%) | 0% | 0 | Common Stock | |
| Annie McGuire | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 42,175 | 42,175 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 11 Jan 2022 | 5,000 | 43,720 (0%) | 0% | 4 | 20,000 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 5,000 | 28,750 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 17 Dec 2021 | 5,000 | 8,720 (0%) | 0% | 45 | 225,000 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.12 per share. | 17 Dec 2021 | 5,000 | 13,720 (0%) | 0% | 12.1 | 60,600 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 11,286 | 1,844 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Executive Chairwoman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 09 Dec 2021 | 11,286 | 73,542 (0%) | 0% | 8.9 | 99,994 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 39.69 per share. | 06 Dec 2021 | 4,375 | 49,662 (0%) | 0% | 39.7 | 173,644 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.55 per share. | 06 Dec 2021 | 1,750 | 54,037 (0%) | 0% | 26.6 | 46,463 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 06 Dec 2021 | 4,375 | 52,287 (0%) | 0% | 24.7 | 108,019 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 37.26 per share. | 06 Dec 2021 | 1,785 | 47,912 (0%) | 0% | 37.3 | 66,510 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 36.11 per share. | 06 Dec 2021 | 3,897 | 49,697 (0%) | 0% | 36.1 | 140,709 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 35.37 per share. | 06 Dec 2021 | 3,550 | 53,594 (0%) | 0% | 35.4 | 125,565 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 06 Dec 2021 | 4,406 | 53,394 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 06 Dec 2021 | 3,750 | 57,144 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 1,750 | 0 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 4,375 | 39,375 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 3,750 | 18,750 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 4,406 | 4,407 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 41.55 per share. | 06 Dec 2021 | 1,750 | 47,912 (0%) | 0% | 41.6 | 72,713 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.22 per share. | 02 Dec 2021 | 2,288 | 62,256 (0%) | 0% | 39.2 | 89,735 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.22 per share. | 02 Dec 2021 | 912 | 48,988 (0%) | 0% | 39.2 | 35,769 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 49015.00 per share. | 01 Nov 2021 | 2,959 | 1,241 (0%) | 0% | 49015 | 145,035,385 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 47.72 per share. | 01 Nov 2021 | 200 | 4,200 (0%) | 0% | 47.7 | 9,545 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 49.48 per share. | 01 Nov 2021 | 1,241 | 0 (0%) | 0% | 49.5 | 61,409 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.80 per share. | 01 Nov 2021 | 149 | 49,900 (0%) | 0% | 51.8 | 7,718 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 50.18 per share. | 17 Sep 2021 | 2,600 | 217,478 (0%) | 0% | 50.2 | 130,478 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Sale of securities on an exchange or to another person at price $ 50.03 per share. | 10 Sep 2021 | 1,900 | 220,078 (0%) | 0% | 50.0 | 95,050 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 07 Sep 2021 | 4,375 | 63,506 (0%) | 0% | 24.7 | 108,019 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 4,375 | 43,750 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 3,750 | 22,500 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 4,406 | 8,813 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 50.53 per share. | 07 Sep 2021 | 926 | 50,049 (0%) | 0% | 50.5 | 46,791 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 51.23 per share. | 07 Sep 2021 | 497 | 50,975 (0%) | 0% | 51.2 | 25,463 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 50.52 per share. | 07 Sep 2021 | 12,034 | 51,472 (0%) | 0% | 50.5 | 607,946 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 07 Sep 2021 | 3,750 | 59,131 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 07 Sep 2021 | 4,406 | 55,381 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.97 per share. | 02 Sep 2021 | 2,288 | 64,544 (0%) | 0% | 53.0 | 121,195 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.97 per share. | 02 Sep 2021 | 912 | 50,975 (0%) | 0% | 53.0 | 48,309 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 43.54 per share. | 02 Aug 2021 | 2,846 | 5,954 (0%) | 0% | 43.5 | 123,926 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 44.57 per share. | 02 Aug 2021 | 1,554 | 4,400 (0%) | 0% | 44.6 | 69,268 | Common Stock |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 34,000 | 34,000 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 39.75 per share. | 23 Jun 2021 | 4,375 | 51,887 (0%) | 0% | 39.8 | 173,914 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2021 | 4,375 | 48,125 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 23 Jun 2021 | 4,375 | 56,262 (0%) | 0% | 24.7 | 108,019 | Common Stock |
| Evan Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 38,720 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| John L. Bishop | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| Jens Holstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 10,720 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 04 Jun 2021 | 4,406 | 57,218 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2021 | 3,750 | 26,250 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2021 | 4,406 | 13,219 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 35.17 per share. | 04 Jun 2021 | 4,979 | 51,887 (0%) | 0% | 35.2 | 175,112 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 34.39 per share. | 04 Jun 2021 | 2,595 | 56,866 (0%) | 0% | 34.4 | 89,251 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 33.28 per share. | 04 Jun 2021 | 1,507 | 59,461 (0%) | 0% | 33.3 | 50,151 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 04 Jun 2021 | 3,750 | 60,968 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Jens Holstein | Director | Purchase of securities on an exchange or from another person at price $ 35.19 per share. | 03 Jun 2021 | 2,000 | 2,000 (0%) | 0% | 35.2 | 70,389 | Common Stock |
| Bonnie H. Anderson | Director, Executive Chairwoman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.07 per share. | 02 Jun 2021 | 2,288 | 189,725 (0%) | 0% | 36.1 | 82,528 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.07 per share. | 02 Jun 2021 | 912 | 52,812 (0%) | 0% | 36.1 | 32,896 | Common Stock |
| Marc A. Stapley | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 46,807 | 46,807 (0%) | 0% | 0 | Common Stock | |
| Marc A. Stapley | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 138,051 | 138,051 | - | - | Stock Option (right to buy) | |
| Beverly Jane Alley | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 5,500 | 13,000 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2021 | 14,065 | 166,117 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 17 May 2021 | 14,065 | 192,013 (0%) | 0% | 5.6 | 78,905 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 48.01 per share. | 03 May 2021 | 3,527 | 9,700 (0%) | 0% | 48.0 | 169,344 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 03 May 2021 | 650 | 9,050 (0%) | 0% | 49.0 | 31,849 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 50.03 per share. | 03 May 2021 | 250 | 8,800 (0%) | 0% | 50.0 | 12,507 | Common Stock |
| Beverly Jane Alley | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 11,541 | 11,541 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 04 Mar 2021 | 4,407 | 84,489 (0%) | 0% | 6.0 | 26,354 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 04 Mar 2021 | 3,750 | 88,239 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 04 Mar 2021 | 17,500 | 105,739 (0%) | 0% | 24.7 | 432,075 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 49.22 per share. | 04 Mar 2021 | 2,991 | 74,026 (0%) | 0% | 49.2 | 147,210 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 47.11 per share. | 04 Mar 2021 | 20,239 | 85,500 (0%) | 0% | 47.1 | 953,544 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 04 Mar 2021 | 5,313 | 80,082 (0%) | 0% | 9.1 | 48,083 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 48.29 per share. | 04 Mar 2021 | 8,483 | 77,017 (0%) | 0% | 48.3 | 409,608 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 17,500 | 52,500 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 3,750 | 30,000 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 4,407 | 17,625 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 5,313 | 0 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 55.49 per share. | 04 Mar 2021 | 300 | 53,724 (0%) | 0% | 55.5 | 16,647 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 54.72 per share. | 04 Mar 2021 | 1,431 | 54,024 (0%) | 0% | 54.7 | 78,310 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 53.50 per share. | 04 Mar 2021 | 2,606 | 55,455 (0%) | 0% | 53.5 | 139,414 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 52.38 per share. | 04 Mar 2021 | 5,032 | 58,061 (0%) | 0% | 52.4 | 263,564 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 51.38 per share. | 04 Mar 2021 | 8,114 | 63,093 (0%) | 0% | 51.4 | 416,901 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 50.40 per share. | 04 Mar 2021 | 2,819 | 71,207 (0%) | 0% | 50.4 | 142,073 | Common Stock |
| Keith Kennedy | COO / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.15 per share. | 02 Mar 2021 | 5,783 | 116,858 (0%) | 0% | 62.1 | 359,413 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.15 per share. | 02 Mar 2021 | 6,320 | 177,948 (0%) | 0% | 62.2 | 392,788 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.15 per share. | 02 Mar 2021 | 5,995 | 74,769 (0%) | 0% | 62.1 | 372,589 | Common Stock |
| Keith Kennedy | COO / CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Keith Kennedy | COO / CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 15,000 | 122,641 (0%) | 0% | 0 | Common Stock | |
| James H. Erlinger | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 7,500 | 7,500 (0%) | 0% | 0 | Common Stock | |
| James H. Erlinger | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 20,000 | 184,268 (0%) | 0% | 0 | Common Stock | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 12,500 | 80,764 (0%) | 0% | 0 | Common Stock | |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 61.09 per share. | 25 Feb 2021 | 3,606 | 200 (0%) | 0% | 61.1 | 220,299 | Common Stock |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 60.03 per share. | 25 Feb 2021 | 2,444 | 3,806 (0%) | 0% | 60.0 | 146,706 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 25 Feb 2021 | 6,250 | 6,250 (0%) | 0% | 4 | 25,000 | Common Stock |
| Karin Eastham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 6,250 | 0 | - | - | Stock Option (right to buy) | |
| Karin Eastham | Director | Sale of securities on an exchange or to another person at price $ 61.77 per share. | 25 Feb 2021 | 200 | 0 (0%) | 0% | 61.8 | 12,354 | Common Stock |
| Keith Kennedy | COO / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.30 per share. | 24 Feb 2021 | 11,046 | 107,641 (0%) | 0% | 62.3 | 688,166 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.30 per share. | 24 Feb 2021 | 39,488 | 164,268 (0%) | 0% | 62.3 | 2,460,102 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.30 per share. | 24 Feb 2021 | 10,048 | 68,264 (0%) | 0% | 62.3 | 625,990 | Common Stock |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Evan Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.36 per share. | 22 Jan 2021 | 5,000 | 30,000 (0%) | 0% | 2.4 | 11,800 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 18,541 | 180,182 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 51.26 per share. | 13 Jan 2021 | 12,177 | 203,756 (0%) | 0% | 51.3 | 624,180 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 50.64 per share. | 13 Jan 2021 | 6,364 | 215,933 (0%) | 0% | 50.6 | 322,283 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 13 Jan 2021 | 18,541 | 222,297 (0%) | 0% | 5.6 | 104,015 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 20,354 | 198,723 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 5,923 | 219,077 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 11 Jan 2021 | 65,182 | 268,938 (0%) | 0% | 8.9 | 577,513 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 65,182 | 13,130 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 51.20 per share. | 11 Jan 2021 | 400 | 203,756 (0%) | 0% | 51.2 | 20,480 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 50.29 per share. | 11 Jan 2021 | 15,568 | 204,156 (0%) | 0% | 50.3 | 782,982 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 49.77 per share. | 11 Jan 2021 | 4,386 | 219,724 (0%) | 0% | 49.8 | 218,311 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 11 Jan 2021 | 20,354 | 224,110 (0%) | 0% | 5.6 | 114,186 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 51.56 per share. | 11 Jan 2021 | 11,497 | 203,756 (0%) | 0% | 51.6 | 592,751 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 50.90 per share. | 11 Jan 2021 | 34,257 | 215,253 (0%) | 0% | 50.9 | 1,743,839 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 49.81 per share. | 11 Jan 2021 | 25,351 | 249,510 (0%) | 0% | 49.8 | 1,262,713 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.61 per share. | 11 Jan 2021 | 5,923 | 274,861 (0%) | 0% | 5.6 | 33,228 | Common Stock |
| Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 49.27 per share. | 04 Jan 2021 | 5,523 | 0 (0%) | 0% | 49.3 | 272,134 | Common Stock |
| Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 04 Jan 2021 | 10,000 | 10,000 (0%) | 0% | 7.4 | 73,900 | Common Stock |
| Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 48.62 per share. | 04 Jan 2021 | 4,477 | 5,523 (0%) | 0% | 48.6 | 217,664 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 29 Dec 2020 | 25,000 | 203,756 (0%) | 0% | 4 | 100,000 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. | 29 Dec 2020 | 6,313 | 178,756 (0%) | 0% | 2.7 | 16,919 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2020 | 25,000 | 0 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2020 | 6,313 | 0 | - | - | Stock Option (right to buy) | |
| Keith Kennedy | COO / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.08 per share. | 02 Dec 2020 | 944 | 118,117 (0%) | 0% | 55.1 | 51,996 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.08 per share. | 02 Dec 2020 | 1,976 | 172,443 (0%) | 0% | 55.1 | 108,838 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 57.55 per share. | 02 Dec 2020 | 6,094 | 78,312 (0%) | 0% | 57.6 | 350,732 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 3,750 | 33,750 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 4,406 | 22,032 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 5,312 | 5,313 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 56.86 per share. | 02 Dec 2020 | 4,279 | 84,406 (0%) | 0% | 56.9 | 243,285 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 55.78 per share. | 02 Dec 2020 | 3,642 | 88,685 (0%) | 0% | 55.8 | 203,140 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 02 Dec 2020 | 3,750 | 92,327 (0%) | 0% | 20.2 | 75,788 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 02 Dec 2020 | 4,406 | 88,577 (0%) | 0% | 6.0 | 26,348 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 02 Dec 2020 | 5,312 | 84,171 (0%) | 0% | 9.1 | 48,074 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.08 per share. | 02 Dec 2020 | 540 | 78,859 (0%) | 0% | 55.1 | 29,743 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.08 per share. | 02 Dec 2020 | 465 | 73,844 (0%) | 0% | 55.1 | 25,612 | Common Stock |
| Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 46.95 per share. | 12 Nov 2020 | 8,194 | 1,806 (0%) | 0% | 47.0 | 384,722 | Common Stock |
| Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 10,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 47.85 per share. | 12 Nov 2020 | 1,806 | 0 (0%) | 0% | 47.8 | 86,415 | Common Stock |
| Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 12 Nov 2020 | 10,000 | 10,000 (0%) | 0% | 7.4 | 73,900 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.99 per share. | 10 Nov 2020 | 3,993 | 236,238 (0%) | 0% | 41.0 | 163,675 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2020 | 20,000 | 78,312 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2020 | 22,906 | 47,906 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2020 | 22,906 | 47,906 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2020 | 22,906 | 174,419 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2020 | 22,906 | 197,325 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.61 per share. | 10 Nov 2020 | 3,419 | 220,231 (0%) | 0% | 43.6 | 149,117 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.02 per share. | 10 Nov 2020 | 8,218 | 223,650 (0%) | 0% | 43.0 | 353,555 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.01 per share. | 10 Nov 2020 | 4,370 | 231,868 (0%) | 0% | 42.0 | 183,582 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 10 Nov 2020 | 20,000 | 240,231 (0%) | 0% | 8.9 | 177,200 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 43.40 per share. | 06 Nov 2020 | 20,050 | 75,509 (0%) | 0% | 43.4 | 870,076 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 06 Nov 2020 | 21,250 | 95,559 (0%) | 0% | 20.2 | 429,463 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2020 | 21,250 | 38,750 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.19 per share. | 06 Nov 2020 | 1,200 | 74,309 (0%) | 0% | 44.2 | 53,031 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 41.56 per share. | 05 Nov 2020 | 2,660 | 74,442 (0%) | 0% | 41.6 | 110,548 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 05 Nov 2020 | 3,613 | 77,102 (0%) | 0% | 40.0 | 144,506 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 05 Nov 2020 | 3,125 | 77,434 (0%) | 0% | 9.0 | 28,281 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 05 Nov 2020 | 3,281 | 80,715 (0%) | 0% | 6.0 | 19,620 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2020 | 3,281 | 20,782 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2020 | 3,125 | 7,292 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 42.08 per share. | 05 Nov 2020 | 133 | 74,309 (0%) | 0% | 42.1 | 5,597 | Common Stock |
| Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2020 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.60 per share. | 19 Oct 2020 | 10,000 | 10,000 (0%) | 0% | 7.6 | 76,000 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 08 Oct 2020 | 50,000 | 220,231 (0%) | 0% | 38 | 1,900,000 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 50,000 | 98,312 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 08 Oct 2020 | 50,000 | 270,231 (0%) | 0% | 8.9 | 443,000 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.21 per share. | 06 Oct 2020 | 2,500 | 81,899 (0%) | 0% | 20.2 | 50,525 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2020 | 2,500 | 37,500 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 35.21 per share. | 06 Oct 2020 | 2,500 | 79,399 (0%) | 0% | 35.2 | 88,025 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2020 | 20,000 | 148,312 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 31.47 per share. | 10 Sep 2020 | 6,607 | 220,231 (0%) | 0% | 31.5 | 207,926 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 30.61 per share. | 10 Sep 2020 | 13,393 | 226,838 (0%) | 0% | 30.6 | 409,934 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 10 Sep 2020 | 20,000 | 240,231 (0%) | 0% | 8.9 | 177,200 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 04 Sep 2020 | 3,542 | 83,489 (0%) | 0% | 9.0 | 32,055 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 2,937 | 26,438 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 3,542 | 10,625 | - | - | Stock Option (right to buy) | |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 32.24 per share. | 04 Sep 2020 | 2,141 | 79,399 (0%) | 0% | 32.2 | 69,016 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 31.21 per share. | 04 Sep 2020 | 2,350 | 81,540 (0%) | 0% | 31.2 | 73,339 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 04 Sep 2020 | 2,536 | 83,890 (0%) | 0% | 30.1 | 76,208 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 04 Sep 2020 | 2,937 | 86,426 (0%) | 0% | 6.0 | 17,563 | Common Stock |
| Keith Kennedy | COO / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.16 per share. | 02 Sep 2020 | 1,131 | 119,061 (0%) | 0% | 34.2 | 38,635 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.16 per share. | 02 Sep 2020 | 1,976 | 220,231 (0%) | 0% | 34.2 | 67,500 | Common Stock |
| Giulia C. Kennedy | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.16 per share. | 02 Sep 2020 | 540 | 79,947 (0%) | 0% | 34.2 | 18,446 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.16 per share. | 02 Sep 2020 | 325 | 74,309 (0%) | 0% | 34.2 | 11,102 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.78 per share. | 31 Aug 2020 | 473 | 74,634 (0%) | 0% | 33.8 | 15,976 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 9,844 | 24,063 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 9,375 | 10,417 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 19,336 | 2 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 8,835 | 2 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 9,000 | 0 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 53 | 0 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.37 per share. | 31 Aug 2020 | 55,970 | 75,107 (0%) | 0% | 33.4 | 1,867,573 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.98 per share. | 31 Aug 2020 | 9,844 | 131,077 (0%) | 0% | 6.0 | 58,867 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 31 Aug 2020 | 9,375 | 121,233 (0%) | 0% | 9.1 | 84,844 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.45 per share. | 31 Aug 2020 | 19,336 | 111,858 (0%) | 0% | 6.4 | 124,717 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 31 Aug 2020 | 8,835 | 92,522 (0%) | 0% | 8.9 | 78,278 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.34 per share. | 31 Aug 2020 | 9,000 | 83,687 (0%) | 0% | 14.3 | 129,060 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 31 Aug 2020 | 53 | 74,687 (0%) | 0% | 4 | 212 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2020 | 1,400 | 8,837 | - | - | Stock Option (right to buy) | |
| John Walter Hanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 21 Aug 2020 | 1,400 | 76,034 (0%) | 0% | 8.9 | 12,404 | Common Stock |
| John Walter Hanna | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 21 Aug 2020 | 1,400 | 74,634 (0%) | 0% | 36.0 | 50,405 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2020 | 25,000 | 247,207 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 20,000 | 168,312 | - | - | Stock Option (right to buy) | |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.22 per share. | 06 Aug 2020 | 20,000 | 222,207 (0%) | 0% | 32.2 | 644,478 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.86 per share. | 06 Aug 2020 | 20,000 | 242,207 (0%) | 0% | 8.9 | 177,200 | Common Stock |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2020 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2020 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Bonnie H. Anderson | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2020 | 25,000 | 222,207 (0%) | 0% | 0 | Common Stock | |
| Jens Holstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2020 | 35,000 | 35,000 | - | - | 35000 | |
| Jens Holstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2020 | 35,000 | 35,000 | - | - | 35000 | |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 35.56 per share. | 31 Jul 2020 | 16,480 | 93,173 (0%) | 0% | 35.6 | 586,026 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 35.60 per share. | 31 Jul 2020 | 1,200 | 69,653 (0%) | 0% | 35.6 | 42,714 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 35.13 per share. | 31 Jul 2020 | 18,800 | 70,853 (0%) | 0% | 35.1 | 660,403 | Common Stock |
| Evan Jones | Director | Sale of securities on an exchange or to another person at price $ 36.16 per share. | 31 Jul 2020 | 3,520 | 89,653 (0%) | 0% | 36.2 | 127,280 | Common Stock |